Based on research at Institute for Cancer Research, Nuvectis Pharma is working on precision medicines for cancer.

Nuvectis, a US-based biopharmaceutical company focused on oncology based on research at University of London’s Institute of Cancer Research (ICR), has completed a $15m series A round backed by undisclosed institutional and private investors. Nuvectis is working on precision medicines for serious conditions of unmet medical need in oncology. It has licensed NXP800, an oral…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.